An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy.
Phase of Trial: Phase II
Latest Information Update: 05 May 2015
At a glance
- Drugs Metreleptin (Primary)
- Indications Diabetes mellitus; Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 25 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Jul 2014 Planned number of patients changed from 50 to 41 as reported by ClinicalTrials.gov.